67625-38-1

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
6-Bromo-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals, owing to its ability to inhibit the Cdc7 kinase enzyme. This makes it a valuable component in the development of drugs targeting cell cycle regulation and cancer treatment.
Used in Cancer Research:
In the field of cancer research, 6-Bromo-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is utilized as a research tool to study the role of Cdc7 kinase in cell cycle progression and its implications in cancer development. Its inhibitory properties allow researchers to investigate the effects of modulating this enzyme on tumor growth and progression.
Used in Drug Development:
6-Bromo-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is employed as a lead compound in drug development, with the aim of creating novel therapeutic agents that can effectively target and inhibit the activity of Cdc7 kinase. This could potentially result in the development of new cancer treatments that are more effective and have fewer side effects.
Used in Chemical Reactions and Synthesis Processes:
Due to its enhanced solubility in organic solvents, 6-Bromo-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a reactant in various chemical reactions and synthesis processes. This allows for the creation of new compounds and the modification of existing ones, expanding the scope of chemical research and application.

InChI:InChI=1/C10H9ClN2O2/c1-2-15-10(14)8-6-13-5-7(11)3-4-9(13)12-8/h3-6H,2H2,1H3

Upstream product

• 1072-98-6 5-chloro-2-pyridylamine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 182181-19-7 6-chloroimidazo[1,2-a]pyridine-2-carboxylic acid 
• 1312585-65-1 ethyl 6-chloro-3-(3-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxylate 
• 1039416-36-8 6-chloroimidazo[1,2-a]pyridine-2-yl-methanol 

Relevant academic research and scientific papers

Improving the Potency of N-Aryl-2,5-dimethylpyrroles against Multidrug-Resistant and Intracellular Mycobacteria

A series of N-phenyl-2,5-dimethylpyrrole derivatives, designed as hybrids of the antitubercular agents BM212 and SQ109, have been synthesized and evaluated against susceptible and drug-resistant mycobacteria strains. Compound 5d, bearing a cyclohexylmethylene side chain, showed high potency against M. tuberculosis including MDR-TB strains at submicromolar concentrations. The new compound shows bacteriostatic activity and low toxicity and proved to be effective against intracellular mycobacteria too, showing an activity profile similar to isoniazid.

Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors

A series of imidazolepyridine derivatives were designed and synthesized according to the established docking studies. The imidazopyridine derivatives were found to have good potency and physical-chemical properties. Several highly potent compounds such as 8ji, 8jl, and 8jm were identified with single nanomolar activities. The most potent compound 8jm showed an IC50 of 3 nM, lower microsome clearance and no CYP inhibition. The profile of 8jm appeared to be superior to BMS433771, and supported further optimization.

SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS

The present invention provides fused derivatives of Formula (I) that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PBKs including, for example, inflammatory disorders, immune- based disorders, cancer, and other diseases.

IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES

The present invention relates to imidazo[1,2-a]pyridine compounds of formula (1) STR1 which are dopamine D-4 antagonists and useful as anti-psychotic agents.